Objective-To examine the association of lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) mass and activity with calcified coronary plaque in young adults. Methods and Results-Nested case-control study among CARDIA participants at the year 15 examination (2000 to 2001, 33 to 45 years old). Cases (nϭ266) were those with and controls (nϭ266) those without evidence of calcified coronary plaque by computed tomography matched 1:1 on sex and race. Lp-PLA 2 mass and activity were significantly higher in cases (296Ϯ101 ng/mL and 36.4Ϯ12.3 nmol/mL per minute) than in controls (267Ϯ80 ng/mL and 32.9Ϯ11.8 nmol/mL per minute). In age-adjusted conditional logistic regression, the odds ratio (OR) of calcified coronary plaque per 1 standard deviation (SD) increment was 1.40 (95% CI, 1.17 to 1.67) and 1.39 (95% CI, 1.14 to 1.70) for Lp-PLA 2 mass and activity, respectively. After adjusting for multiple covariates including low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides, and C-reactive protein, a statistically significant association remained for Lp-PLA 2 mass (OR, 1.28; 95% CI, 1.03 to 1.60) but not for activity (OR, 1.09; 95% CI, 0.84 to 1.42 
L ipoprotein-associated phospholipase A 2 (Lp-PLA 2 , also termed as platelet-activating factor acetylhydrolase [PAF-AH]) is a 441-amino acid calcium-independent enzyme synthesized by macrophages and platelets that exists in 2 forms: intracellular and circulating in plasma, 80% bound to LDL particles. [1] [2] [3] Lp-PLA 2 hydrolyzes oxidized phospholipids generating chemotactic/pro-atherogenic byproducts (lysophosphatidylcholine and oxidized fatty acids). 3 Additionally, it inactivates platelet-activating factor and thus may also be anti-inflammatory/antithrombotic. 4 Three epidemiological studies have been published focusing on Lp-PLA 2 mass, and the results are not entirely consistent. In the West of Scotland Coronary Prevention Study, Lp-PLA 2 mass had a strong, positive association with risk of major coronary events, independently of cardiovascular disease risk factors. 5 In the Women's Health Study, the association between Lp-PLA 2 mass and all cardiovascular disease was markedly attenuated and became nonstatistically significant after risk factor adjustment. 6 In the ARIC Study, Lp-PLA 2 mass independently predicted risk of incident coronary heart disease among individuals below median LDL cholesterol (LDL-C Ͻ130 mg/dL). 7 Lp-PLA 2 or PAF-AH activity has been examined in the context of multiple inflammatory pathologies. Whereas Lp-PLA 2 activity may be upregulated as part of the acute phase response, 8 -10 it may be downregulated in the context of different disease states or therapies. [11] [12] [13] [14] [15] [16] In the AtheroGene study, individuals within the highest quartile of PAF-AH activity had a 1.8-fold increase in coronary artery disease (CAD) risk (95% CI, 1.01 to 3.2) compared with those in the first quartile and after adjusting for clinical and metabolic factors. 17 The aims of this investigation were to describe the demographic, lifestyle, and biochemical correlates of Lp-PLA 2 mass and activity in a sample of white and black young adults and to characterize the association of Lp-PLA 2 mass and activity with the presence of calcified coronary plaque ascertained by cardiac computed tomography (CT).
Methods
The Coronary Artery Risk Development in Young Adults (CAR-DIA) study is an ongoing investigation of heart disease risk factors and subclinical CAD among black and white men and women aged 18 through 30 years at study inception in 1985 to 1986. More details of study design, recruitment, and procedures have been published elsewhere. 18, 19 Participants were recruited in 4 field centers: Birmingham, Ala; Chicago, Ill; Minneapolis, Minn; and Oakland, Calif.
A nested case-control study design was used with data collected at the CARDIA Year 15 examination (June 2000 to October 2001), in which the participants were between the ages of 33 and 45. Cases (nϭ266) were all study participants who had evidence of calcified coronary plaque (ie, coronary calcium score Ͼ0), and controls were members with a calcium score of zero individually matched to cases based on sex and race. Of the original 282 cases, 16 were excluded in the final analysis for missing data on covariates of interest.
Age, race/ethnicity, and educational attainment were ascertained by self-report. Alcohol and tobacco use were ascertained by selfreport and by interviewer-administered questionnaire if the participant reported ever drinking or smoking. 20 Blood samples were drawn after an overnight fast. The protocols for lipid determination can be found elsewhere. [21] [22] [23] Anthropometric measures (weight, height, waist and hip girths) were performed according to the CARDIA study protocol. 24 Body mass index was calculated as weight/height 2 (kg/m 2 ). Fasting plasma glucose was determined at Linco Research Inc using the hexokinase-ultraviolet method. 25 C-reactive protein (CRP) was measured with an ultrasensitive enzyme-linked immunosorbent assay based on purified protein and polyclonal anti-CRP antibodies (Calbiochem). 26 Hypertension was defined as self-report of hypertension and/or systolic blood pressure Ն140 mm Hg and diastolic blood pressure Ն90 mm Hg and/or use of antihypertensive medication. Diabetes was defined as self-report of diabetes mellitus and/or fasting blood glucose Ն126 mg/dL and/or use of antidiabetic medication. Hormone replacement therapy and use of cholesterol lowering medication were ascertained by self-report. The institutional review boards of the field centers approved the study, and all participants gave informed written consent.
Measurement of Lp-PLA 2 Mass and Activity
Lp-PLA 2 mass was measured using a 2-site enzyme-linked immunoabsorbent assay (diaDexus Inc, South San Francisco, Calif) on serum samples stored at Ϫ70°C for an average of 18 months. 27 The highest standard in the assay is 1000 ng/mL and the lowest limit of detection is 1 ng/mL. The interassay coefficient of variation was 20%. The correlation between split Lp-PLA 2 mass measurements in 119 randomly selected samples was 0.91.
Lp-PLA2 activity was measured at the Molecular Epidemiology and Biomarker Research Laboratory (University of Minnesota, Minneapolis) using a method described by Stafforini et al 28 with slight modifications. We used Sep-Pak Plus C18 cartridges from Waters instead of Kaker Chemical Co, and our units are reported as nmol/mL per minute instead of mol/mL per hour. The substrate for this analysis was obtained from Avanti Polar Lipids part number 840009. The interassay coefficient of variation was 9%, and in 294 split sample pairs the correlation was 0.76.
CT Scanning Protocol
Two scans were obtained on each participant, 1 to 2 minutes apart. Participants were scanned in supine position (without getting off the table between scans) over a hydroxy-apatite phantom to adjust for scanner and participant differences in CT attenuation numbers (ie, Hounsfield units) across field centers. The Chicago and Oakland field centers used Imatron C-150 scanners, the Birmingham field center used a GE Lightspeed Qxi scanner, and the Minneapolis field center used a Siemens VZ scanner. An experienced and trained CT image analyst (blinded to nonscan data and to the order of images) identified the courses of the coronary arteries using specially developed image-processing software and calculated an Agatston score modified to account for slice width and adjusted to standardized CT attentuations values based on the calibration phantom, which was imaged with each participant. 29 Additional details of the phantom calibration and CT protocol can be found in our previous publications. 30, 31 In the analysis, we used the mean of the 2 readings. There were 2921 (96.5%) concordant positive (score Ͼ0) or concordant negative (scoreϭ0) scans and 107 (3.5%) discordant scans (ie, one zero scan and one nonzero scan). Of the discordant scans, 9 (8%), 33 (31%), 4 (4%), 56 (%), and 5 (5%) were adjudicated to definitely negative, probably negative, cannot tell, probably positive, and definitely positive, respectively. For the first 3 categories, the adjudicated score was set to zero; for the last 2 categories, the adjudicated score was set to the score of the positive scan. A second expert reader who was not from the Reading Center trained in the software usage reviewed 100 discordant scan pairs using the same adjudication process. The agreement was 91%.
Statistical Analysis
Univariate case-control differences were ascertained using the t test for normally distributed continuous variables, the Wilcoxon ranksum test for continuous variables that were not normally distributed (alcohol intake, triglycerides and CRP), and the 2 test for categorical variables. To assess bivariate associations of Lp-PLA 2 mass and activity with other covariates, we computed means and SD (or proportions) of the covariates according to sex-/race-specific tertiles of Lp-PLA 2 mass and activity, respectively. Tests for linear trend were estimated using the significance of Pearson correlation coefficients for continuous variables and the Cochran-Armitage test for 2 by n categorical variables. Heterogeneity of means across groups was assessed with analysis of variance (ANOVA). Conditional logistic regression was then applied to quantify the relative odds of calcified coronary plaque (ie, calcium score Ͼ0 versus calcium scoreϭ0) associated with 1 (sex-and race-specific) SD linear increment in Lp-PLA 2 mass and activity, respectively. We also implemented conditional logistic models with Lp-PLA 2 mass and activity entered as [sex-and race-specific] tertiles 2, 3 with tertile 1 as the reference group. Both the SD and the tertile cutpoints were estimated among controls. Because of the high correlation between mass and activity, we performed separate models for mass and activity. Three sequential models were fitted: model 1, adjusting for age only (sex and race are adjusted for by design); model 2, adjusting for (in addition to age) education attainment, alcohol consumption, cigarette smoking, body mass index, waist circumference, diabetes and hypertension; model 3, further adjusting for LDL-C, highdensity lipoprotein cholesterol (HDL-C), and triglycerides; and model 4, further adjusting for CRP. We also considered a variation of model 3 that included only LDL-C.
Because of previous epidemiological evidence indicating a stronger association of Lp-PLA 2 mass among individuals with low LDL-C, 7 we tested the significance (in fully adjusted models) of interactions of Lp-PLA 2 mass and activity with LDL-C as predictors of calcified coronary plaque. Because none of the interactions was statistically significant (P for interaction between Lp-PLA 2 mass and LDL-Cϭ0.52; P for interaction between Lp-PLA 2 activity and LDL-Cϭ0.68), we did not perform stratified analyses by LDL-C level. The SAS software, version 8 (SAS Institute), was used in all statistical analyses.
To examine whether there is a quantitative relationship between Lp-PLA 2 mass and activity and coronary artery calcium (not just presence or absence of calcified coronary plaque), we used an alternative analytical approach consisting of linear regression models with log (calcium score ϩ1) as the dependent variable, Lp-PLA 2 mass, and activity as continuous predictors and the same covariate adjustment sequence (ie, models 1 through 4). This strategy has proven to detect associations with cardiovascular risk factors in previous studies. 32 
Results
Compared with controls, cases tended to be slightly older (by 1.5 years) and had lower educational attainment (Table 1) . Cases were significantly more likely to be current smokers, to have a history of hypertension, and to be using cholesterol-lowering medication. Although diabetes was twice as common in cases as in controls, this difference did not reach statistical significance. Hormone replacement therapy was very rare in our sample (Ͻ3%) and did not differ by case-control status. Waist circumference, LDL-C, and triglycerides were significantly higher, whereas HDL-C was significantly lower in cases compared with controls. Both Lp-PLA 2 mass and activity were significantly higher in cases than in controls. However, no statistically significant differences were found for alcohol intake, body mass index, and CRP level between cases and controls. Among the cases, the average (ϮSD) calcium score was 85 (Ϯ 272); approximately half of the cases had a calcium score Ͻ20 and 32% had a calcium score of Ն50. In descriptive analysis combining cases and controls (Figure 1 ), Lp-PLA 2 mass was highest in white men, followed by white women, black men, and black women (P ANOVA Ͻ0.0001). In turn, Lp-PLA 2 activity was highest in white men, followed by black men, white women, and black women (P ANOVA Ͻ0.0001).
Means of waist circumference, LDL-C, and triglycerides increased and HDL-C decreased linearly with the levels of both Lp-PLA 2 mass and activity (Table 2 ). There were also significant positive linear trends of age and educational attainment across levels of Lp-PLA 2 activity. There were no discernible trends with all the other covariates. The Pearson linear correlation between Lp-PLA 2 mass and activity was 0.61; Lp-PLA 2 mass correlated 0.39 with LDL-C and Ϫ0.25 with HDL-C; Lp-PLA 2 activity correlated 0.52 with LDL-C and Ϫ0.33 with HDL-C. The Spearman rank-order correlation with triglycerides was 0.11 for mass and 0.33 for activity.
The proportion of cases with calcified coronary plaque increased in a stepwise fashion with tertiles of both Lp-PLA 2 mass and activity in both men and women (Figure 2) .
In age-adjusted conditional logistic regression (model 1), Lp-PLA 2 mass and activity were significantly associated with calcified coronary plaque (odds ratio [OR] per 1 standard deviation [SD] incrementϭ1.40; 95% CI, 1.17 to 1.67 for mass; OR, 1.39; 95% CI, 1.14 to 1.70 for activity) ( Table 3) . Ageadjusted OR for the upper tertile, relative to the lowest tertile, were 2.15 (95% CI, 1.36 to 3.42) for mass and 2.40 (95% CI, 1.52 to 3.81) for activity. After adjusting for age, educational attainment, smoking status, alcohol consumption, body mass index, waist circumference, diabetes, and hypertension (model 2), the risk relations did not change appreciably. Further adjustment for LDL-C, HDL-C, and triglycerides (model 3) resulted in attenuation of the strength of the associations but, whereas Lp-PLA 2 mass remained significantly related, Lp-PLA 2 activity was no longer significantly related to calcified coronary plaque. In a variation of model 3 with entry of LDL-C alone (in addition to model 2 covariates), the OR associated with 1 SD increment of Lp-PLA 2 mass was 1.29 (95% CI, 1.04 to 1.60), and the OR associated with 1 SD increment of Lp-PLA 2 activity was 1.18 (95% CI, 0.91 to 1.52). Further adjustment for CRP (Model 4) did not change the results.
In the linear model of log (calcium score ϩ1), the slope estimates associated with 1 SD increment (standard error; P) were as follows (first value is for Lp-PLA 2 
Discussion
This study documents, for the first time to our knowledge in young adults, an independent association of Lp-PLA 2 mass with presence of calcified coronary plaque and amount of coronary calcium and thus supports the notion that Lp-PLA 2 may be relevant to atherogenesis. In this regard, recent evidence indicates that Lp-PLA 2 has great affinity for small, dense LDL particles, known to be more susceptible to oxidative modification and to be atherogenic, 33 and that Lp-PLA 2 byproducts may be involved in apoptosis of macrophages and smooth muscle cells, a process that can lead to atherosclerosis progression. 34 Our findings confirm and extend earlier results of the West of Scotland Coronary Prevention Study, in which Lp-PLA 2 mass was a strong, independent predictor of coronary events. 5 After adjustment for age, systolic blood pressure, plasma triglycerides, LDL-C, HDL-C, fibrinogen, white cell count, and CRP, an increase of 1 SD in Lp-PLA 2 mass was associated, in Scottish men, with 1.18 increased hazard of coronary events (95% CI, 1.05 to 1.33). Our estimate of the risk relation with calcified coronary plaque, using a slightly different group of covariates, was 1.28 (95% CI, 1.03 to 1.60). Furthermore, in the current analysis, the OR associated with the highest tertile of Lp-PLA 2 mass (2.2) was of similar magnitude to the multivariate OR observed for diabetes (2.6), hypertension (2.2), or current smoking (2.2).
An association was also found between Lp-PLA 2 activity and calcified coronary plaque, but this relationship dropped below the threshold for statistical significance after adjustment for lipids, particularly LDL-C. We believe that the reason behind this attenuation is the stronger correlation between enzymatic activity and LDL-C (rϭ0.52) than between enzymatic mass with LDL-C (rϭ0.39). It could be argued that adjustment for LDL-C may be inappropriate in this case because Lp-PLA 2 may be in the causal pathway connecting LDL oxidation with atherosclerosis, creating statistical colinearity.
Lp-PLA 2 mass and activity differed significantly by sex-race groups, being highest in white men and lowest in black women. In agreement with the data from Packard et al, 5 Lp-PLA 2 mass and CRP were uncorrelated, suggesting that Lp-PLA 2 and CRP represent different metabolic pathways.
The calcification of atheroma occurs early in plaque development as part of the inflammatory pathophysiologic cascade of CAD, and is actively regulated like bone mineralization. 35 
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Although its value in cardiovascular risk stratification is not definitely established, coronary artery calcification may be an independent predictor of angiographic CAD 36 and of coronary events. [37] [38] [39] In our study, CRP was not associated with presence of calcified coronary plaque, a finding that is in agreement with 2 recent studies using coronary calcium scores as the outcome. 40 -42 It has been argued that CRP may measure the degree of plaque destabilization and ongoing ulceration or thrombosis rather than atherosclerotic mass. 43 The strengths of our study include being a population-based, bi-ethnic sample, the lack of interference of treatments (only 29 participants were using cholesterol agents and 4 women were using hormone replacement therapy), and the availability of multiple established cardiac risk factors. The main limitations are the observational and cross-sectional nature of the data (precluding causal inference) and the fact that we have not characterized the CARDIA cohort for known genetic polymorphisms in the PAF-AH gene. A G994 -ϾT missense mutation in exon 9, shown to be present in 4% of Japanese men, has been shown to be associated with reduced Lp-PLA 2 activity and with increased risk of CAD. 44 Further research is needed to reconcile these findings in Japanese men with the findings reported here that increased mass and activity are associated with calcified coronary plaque.
In conclusion, Lp-PLA 2 mass (but not its activity) was independently associated with calcified coronary plaque among young adults. Additional studies are warranted to elucidate the contributions of Lp-PLA 2 bioproducts on the risk of atherothrombosis and the value of selective inhibitors of Lp-PLA 2 activity in combating atherosclerosis. 
